TerminatedNCT03972709
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
PHASE2 · 372 planned enrolment
- Countries listed
- 1
- Registry update
- March 27, 2024
